



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 12408

Title: The role of p53 tumor suppressor in molecular pathogenesis of colorectal cancer and pharmacological reactivation of p53 as cancer therapy

Reviewer code: 00503404

Science editor: Ya-Juan Ma

Date sent for review: 2014-07-08 14:09

Date reviewed: 2014-07-08 19:47

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a comprehensive review on the importance of the p53 pathway in CRC. The only comment is the relative lack of novelty. Comments; 1. Authors should confirm the originality of figures 1 and 2 2. please add a Table with a bullet list of the major conclusions on the importance of p53 in CRC development 3. please highlight where authors discuss sporadic and hereditary cancers throughout the paper



ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 12408

Title: The role of p53 tumor suppressor in molecular pathogenesis of colorectal cancer and pharmacological reactivation of p53 as cancer therapy

Reviewer code: 00056678

Science editor: Ya-Juan Ma

Date sent for review: 2014-07-08 14:09

Date reviewed: 2014-07-25 05:41

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Dear authors, This article is correctly written and interesting in terms of the present and future opportunities of p53 treatment based on the pharmacological reactivation of p53. To increase the understanding, in the first part of the review , it lacks some figures recapping the interactions of p53 in the different cellular pathways (parts 2 and 3). There are a few minor errors : It lacks the page numbers In the paragraph 5.1.1 the third sentence is stopped mild-flow. The number of the paragraph entitled RITA is wrong as it should be 5.1.3. I don't understand the sentence : ? cancer cells often acquire secondary resistance after a prolonged exposure of a single agent, so it is clinically desirable to counter this resistance to treatment with combination therapy ?



ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 12408

Title: The role of p53 tumor suppressor in molecular pathogenesis of colorectal cancer and pharmacological reactivation of p53 as cancer therapy

Reviewer code: 00068832

Science editor: Ya-Juan Ma

Date sent for review: 2014-07-08 14:09

Date reviewed: 2014-07-25 10:03

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

In this review, authors summarized the p53 function and characterize its mutations in colorectal cancer, and depicted the involvement of p53 mutations in pathogenesis of colorectal cancer and their clinical impacts. Moreover, authors also described the current achievements of using p53 modulators to reactivate this pathway in CRC, and depicted the evolvement of pharmacological study on specifically targeting mutant oncogenic p53. Thus, I think this paper is acceptable. A write error in little captions: 6.1.3 RITA → 5.1.3 RITA